In September 2024, the Department of Justice (DOJ) released an updated version of its Evaluation of Corporate Compliance Programs (ECCP) Guidance. The ECCP serves as a framework for DOJ prosecutors to evaluate a company’s compliance program when considering the appropriate enforcement actions. While updates were made across multiple topics, the most notable changes focus on […]
Portsmouth, NH – January 27, 2025 — MediSpend, a global technology company providing best-in-class solutions for the life sciences industry, announces its acquisition of Real Life Sciences (RLS), a leader in advanced anonymization solutions for clinical trial and other data. MediSpend’s second acquisition in less than a year reinforces its commitment to expanding its presence […]
In the competitive landscape of life sciences, building and nurturing strong relationships with key opinion leaders (KOLs) is crucial for success. These influential experts are at the forefront of medical innovation, driving drug advocacy and shaping the future of healthcare. Managing these relationships effectively, while ensuring full compliance, can be a complex challenge. MediSpend’s KOL […]
Listen as our experts discuss the importance of identifying and partnering with the right KOLs.
Key topics include:
In today’s life sciences organizations, the importance of effectively auditing and monitoring interactions with healthcare professionals (HCPs) cannot be overstated. Data analytics is a powerful tool which enables organizations to gain insights and ensure compliance while optimizing engagement strategies.
In this webinar, MediSpend experts highlight the significance of data analytics in auditing and monitoring interactions with […]
The elements of an effective compliance program provide a framework for life sciences companies to ensure their program is comprehensive and practicable. These same elements can be tailored to create an effective compliance training program for transparency reporting. By applying this framework to your transparency training, companies can enhance compliance with transparency reporting obligations, ensuring […]
In recent years, anti-bribery and anti-corruption enforcement penalties have been increasing in number and size, and recent actions illustrate that third parties continue to be a concern. For life sciences companies, managing these risks is crucial to complying with laws such as the US Anti-Kickback Statute, the Foreign Corrupt Practices Act and the UK Bribery […]
The transparency landscape for the life science industry is continuously evolving, with requirements that seem to be increasing by the minute. At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, industry professionals discussed the latest regulations impacting both pharmaceutical and medical device companies. Two areas stood out during these discussions: Illinois and Brazil.
Illinois
House Bill 5517 […]
At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]
At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]
